AstraZeneca: IMFINZI improved event-free survival, OS across MIBC
Results from a post-hoc exploratory subgroup analysis from the NIAGARA Phase III trial showed AstraZeneca’s (AZN) IMFINZI, ...
Medical Dialogues12d
Transanal TME Proves Noninferior to Laparoscopic Approach in 3-Year Disease-Free Survival for Rectal Cancer: TaLaR Trial
The 3-year local recurrence rate was 3.6% for transanal TME and 4.4% for laparoscopic TME. The 3-year overall survival was 92 ...
Physician's Weekly1d
Zenocutuzumab Shows Promise in NRG1 Fusion–Positive Cancer
The following is a summary of “Efficacy of Zenocutuzumab in NRG1 Fusion–Positive Cancer,” published in the February 2025 ...
Bristol Myers Squibb Cancer Treatment Misses Primary Endpoint in Trial
Bristol Myers Squibb said it is disappointed with the outcome of a study that examined whether one of its drugs could be used to treat a certain type of skin cancer. The drug, Opdualag, didn't meet ...
Business Wire5d
Orca Bio’s Orca-T® Meets Primary Endpoint in the Pivotal Precision-T Phase 3 Clinical Study for Hematologic Malignancies
Orca Bio announces it met the primary endpoint in its pivotal Phase 3 clinical study for its lead allogeneic T-cell immunotherapy, Orca-T.